摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯 | 1160248-35-0

中文名称
4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯
中文别名
4,6-二氢吡咯并[3,4-c]吡唑-3,5(1H)-二甲酸5-叔丁酯;4,6-二氢吡咯并[3,4-c]吡唑-3,5(1H)-二羧酸-5-(1,1-二甲基乙基)酯
英文名称
5-(Tert-butoxycarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-carboxylic acid
英文别名
5-[(2-methylpropan-2-yl)oxycarbonyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-3-carboxylic acid
4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯化学式
CAS
1160248-35-0
化学式
C11H15N3O4
mdl
——
分子量
253.25
InChiKey
SBFDXYJFMPRVOE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    480.1±45.0 °C(Predicted)
  • 密度:
    1.400

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    95.5
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933990090

反应信息

  • 作为反应物:
    描述:
    4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯4-(2-三氟甲基苯基)哌啶盐酸盐卡特缩合剂N,N-二异丙基乙胺乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 silica gel 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 16.0h, 以to give tert-butyl 3-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate as a white solid (13, 0.560 g, 100%)的产率得到tert-butyl 3-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate
    参考文献:
    名称:
    4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
    摘要:
    本发明提供了一种化合物,其结构为:(结构式表示),其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基;R6为H、OH或卤素;B为取代或未取代杂环、吡嗪、吡唑、吡嗪、噻二唑或三唑,其中杂环不是氯取代的吲哚;当吡唑取代时,取代基不是三氟甲基,或其药学上可接受的盐。
    公开号:
    US20160046648A1
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20150315197A1
    公开(公告)日:2015-11-05
    The present invention provides a compound having the structure: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl, wherein two or more of R 1 , R 2 , R 3 , R 4 , or R 5 are other than H; R 6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is H, R 2 is CF 3 , R 3 is H, R 4 is CF 3 , and R 5 is H, or R 1 is Cl, R 2 is H, R 3 is H, R 4 is F, and R 5 is H, or R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is CF 3 , R 2 is F, R 3 is H, R 4 is H, and R 5 is H, or R 1 is Cl, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, then B is other than or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基,其中R1、R2、R3、R4或R5中的两个或更多个不是H;R6为H、OH或卤素;B为取代或未取代的杂环,其中当R1为CF3、R2为H、R3为F、R4为H和R5为H,或者R1为H、R2为CF3、R3为H、R4为CF3和R5为H,或者R1为Cl、R2为H、R3为H、R4为F和R5为H,或者R1为CF3、R2为H、R3为F、R4为H和R5为H,或者R1为CF3、R2为F、R3为H、R4为H和R5为H,或者R1为Cl、R2为F、R3为H、R4为H和R5为H时,则B不是或其药学上可接受的盐。
  • OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160024007A1
    公开(公告)日:2016-01-28
    The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.
    本发明提供了八氢环戊吡咯化合物,其结构如下:(结构式表示),其中psi不存在或存在,当存在时为键;R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基;R6不存在或存在,当存在时为H、OH或卤素;A不存在或存在,当存在时为C(O)或C(O)NH;B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H,其中当B为CO2H时,A存在且为C(O);当psi存在时,R6不存在,当psi不存在时,R6存在,或其药学上可接受的盐,用于治疗以视网膜过多脂褐质沉积为特征的疾病。
  • OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160046632A1
    公开(公告)日:2016-02-18
    The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.
    本发明提供了包含各种取代的八氢吡咯吡咯化合物,它们的合成方法,制备方法,使用方法,以及它们的组成和配方。
  • N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160046649A1
    公开(公告)日:2016-02-18
    The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is alkyl; A is absent or present, and when present is —C(O)— or —C(O)NH—; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is —C(O)—, or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:(结构表示)其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基;R6为烷基;A不存在或存在,当存在时为—C(O)—或—C(O)NH—;B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H,其中当B为CO2H时,A存在且为—C(O)—,或其药学上可接受的盐。
  • Substituted 4-phenylpiperidines, their preparation and use
    申请人:Petrukhin Konstantin
    公开号:US09434727B2
    公开(公告)日:2016-09-06
    The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is Cl, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is Cl, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有以下结构的化合物:其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基,其中R1、R2、R3、R4或R5中的两个或两个以上不是H;R6为H、OH或卤素;B为取代或未取代的杂环,其中当R1为CF3,R2为H,R3为F,R4为H和R5为H,或者R1为H,R2为CF3,R3为H,R4为CF3和R5为H,或者R1为Cl,R2为H,R3为H,R4为F和R5为H,或者R1为CF3,R2为H,R3为F,R4为H和R5为H,或者R1为CF3,R2为F,R3为H,R4为H和R5为H,或者R1为Cl,R2为F,R3为H,R4为H和R5为H时,则B不是或其药学上可接受的盐。
查看更多

同类化合物

奥格列汀 吡唑并[3,4-a]吡咯里嗪 叔丁基3'-氨基-1',4'-二氢-5'H-螺[环丁烷-1,6'-吡咯并[3,4-C]吡唑]-5'-羧酸酯 5-苄基-1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-羧酸乙酯 5-甲基-1H,4H,5H,6H-吡咯并[3,4-C]吡唑 5-叔丁基3-乙基4,6-二氢吡咯并[3,4-c]吡唑-3,5(1h)-二羧酸 5-叔丁基1-乙基3-氨基-3A,4,6,6A-四氢吡咯并[3,4-C]吡唑-1,5-二甲酯 5-BOC-3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-1-甲酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-羧酸 5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸 5,6-二氢-3-羟基-4H-吡咯并[1,2-c][1,2,3]恶二唑-7-鎓内盐 4a,6c-二氮杂环丁[a]环戊二烯并[Cd]并环戊二烯 4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯 4,6-二氢-1H-吡咯[3,4-C]吡唑-5-甲酸丁酯 3-甲基-1,4,5,6-四氢-吡咯并[3,4-c]吡唑 3-溴-5,6-二氢-4H-吡咯并[1,2-b]吡唑 3-氨基-6-乙基-4,6-二氢吡咯并[3,4-C]吡唑-5(1H)-羧酸叔丁酯 3-氨基-6,6-二甲基-4,6-二氢吡咯并[3,4-C]吡唑-5(2H)-羧酸叔丁酯 3-氨基-6,6-二甲基- 吡咯并[3,4-c]吡唑-2,5(4H,6H)-二羧酸 5-(1,1-二甲基乙基) 2-乙酯 3-氨基-5-叔丁氧羰基-吡咯并[3,4-C]吡唑 3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-5-甲酸叔丁酯 3-氨基-4,6-二氢-6,6-二甲基-吡咯并[3,4-c]吡唑-1,5-二甲酸 5-叔丁基 1-乙基酯 3-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)-5,6-二氢-4H-吡咯并(1,2-B)吡唑 2-甲基-2-丙基3'-氨基-1',4'-二氢-5'H-螺[环丙烷-1,6'-吡咯并[3,4-c]吡唑]-5'-羧酸酯 2-(甲基磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-羧酸叔丁酯 2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑 2,3-二氮杂三环[5.2.1.02,6]癸-1(9),3,5,7-四烯 1-甲基-1,4,5,6-四氢吡咯并[3,4-c]吡唑盐酸盐 1-(4-四氢吡喃基)-1,4,5,6-四氢吡咯并[3,4-C]吡唑盐酸盐 1-(3-氨基-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基)乙酮 1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-胺 1,4,5,6-四氢吡咯并[3,4-C]吡唑 1,4,5,6-四氢吡咯并-[3,4-c]-吡唑双盐酸盐 1,4,5,6-四氢-1-甲基吡咯并[3,4-C]吡唑 (S)-3-氨基-N-(2-(二甲基氨基)-1-苯基乙基)-6,6-二甲基-4,6-二氢吡咯并[3 (9CI)-2,4,5,6-四氢-2-甲基-吡咯并[3,4-c]吡唑 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-2-cyclopropyl-3-(trifluoromethyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5-isopropylaminocarbonyl-3-phenyl-1-polystyrenenethylaminocarbonyl-4,6-dihydropyrrolo[3,4-c]pyrazole 5-(6-{[(3,4-cis)-3-fluoropiperidin-4-yl]oxy}-5-methylpyrimidin-4-yl)-1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-2-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5,5-dimethyl-2-(6-methylpyridin-2-yl)-3-(pyridine-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 5,5-dimethyl-2-(pyridin-2-yl)-3-(pyridin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 3-bromo-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 1-cyano-2,3,7-triazabicyclo[3.3.0]oct-2-ene 3-(aminomethyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid 1,1-dimethylethyl ester 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-1,3-dimethyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-hydroxy-2-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one